July 2011
Pharma Magazine;Jul/Aug2011, Vol. 7 Issue 4, p6
In this article the author discusses aspects of the Advocate General's (the AG) recommendation on stem cell derived inventions' patentability under European law. He notes the implication of the AG's opinion to the Court of Justice of the European Union (CJEU) and relates it with the Enlarged Board of Appeal of the European Patent Office's decision (EPO) in the Wisconsin Alumni Research Foundation (WARF) case. The controversy involving human embryonic stem cell (HeS) research is also cited.


Related Articles

  • The European Union Ban on Stem Cell Patents. Hemphill, Thomas A. // Research Technology Management;Mar/Apr2012, Vol. 55 Issue 2, p10 

    The author presents his opinion on the European Union's stem cell research policy, focusing on the unanimous October 18, 2011 ruling by the European Court of Justice (ECJ) on the case of Oliver Bruestle v. Greenpeace, which bans patents on inventions related to human embryo research. The author...

  • European ruling risks pushing out the scientists. Webber, Philip // Lawyer;11/14/2011, p6 

    The article offers opinions about the decision of the Court of Justice of the European Union (CJEU) regarding patents based on human stem cells. Topics include the issues of morality used in the case against patents of the cells, the Biotech Directive issued by the European Commission in the...

  • The impact of European embryonic stem cell patent decisions on research strategies. Mahalatchimy, Aurélie; Rial-Sebbag, Emmanuelle; Duguet, Anne-Marie; Taboulet, Florence; Cambon-Thomsen, Anne // Nature Biotechnology;Jan2015, Vol. 33 Issue 1, p41 

    The article focuses on impacts due to human embryonic stem cell (hESC) patent restrictions by the European Patent Office (EPO) and the Court of Justice of the European Union (CJEU) on research and development strategies. It mentions the positive aspects of the same such as shifting of...

  • Stem cells caught in morality clause. Siva, Nayanah // Nature Biotechnology;Feb2009, Vol. 27 Issue 2, p109 

    The article notes a European Patent Office (EPO) November 2008 ruling that it will not issue patents for stem cells derived from human-embryo destruction. EPO's "morality clause" invalidates an EPO patent issued to the University of Wisconsin at Madison. As the ruling does not affect other...

  • Europe rules against stem-cell patents. Abbott, Alison // Nature;3/17/2011, Vol. 471 Issue 7338, p280 

    The article focuses on the issue regarding the threat to ban the European stem-cell researchers from patenting procedures involving embryonic-stem-cell lines. According to the author, the Court of Justice of the European Communities releases an opinion questioning the ethics of their work. The...

  • MORAL DISHARMONY: HUMAN EMBRYONIC STEM CELL PATENT LAWS, WARF, AND PUBLIC POLICY. Shum, Jenny // Boston College International & Comparative Law Review;Winter2010, Vol. 33 Issue 1, p153 

    Human embryonic stem cells have unique regenerative properties and the ability to develop into a variety of different cell types. Based on these properties, stem cell research is considered a promising biomedical field for the development of cell-based therapies to treat diseases. It is also a...

  • BEYOND OUR BORDERS. Greenleaf, Kevin; Benson, Chris; Cheng, David // Landslide;Jul/Aug2013, Vol. 5 Issue 6, p36 

    The article focuses on the post-grant proceedings of patents in China, Europe and the U.S. It states that difference between post-grant proceedings in the U.S. and Europe is in terms of cost and claim construction. It mentions that in China a post-grant opposition procedure need to take place...

  • Innovative change.  // New Scientist;07/19/97, Vol. 155 Issue 2091, p11 

    Reports on the European Patent Office's announcement that it is reducing fees to investors by 20 percent to encourage innovation in Europe.

  • Patent office under fire over consultation. Abbott, Alison // Nature;9/21/1995, Vol. 377 Issue 6546, p188 

    Reports that the European Patent Office (EPO) has come under fire from groups opposed to the patenting of genes and living organisms for failure of the EPO to consult them over draft proposals. Issues over the high cost of European patents; Public controversy over gene patenting.


Read the Article


Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics